Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC

Release Time：2023-01-17 Author： Source: Pageviews：

Previous：COMIRNATY^®Bivalent COVID-19 Vaccine is Officially Approved as Regular Imported Vaccine by the Pharmaceutical Administration Bureau of Macao SAR Next：Fosun Receives RMB12 Billion Syndicated Loan from 8 Banks to Jointly Promote Development of the Private Economy

Latest News

2023-11-30

Fosun International Receives “ESG Leading Enterprise Award” from Bloomberg Businessweek/Chinese Edition
2023-11-23

Henlius Receives the FDA IND Approval for Its EGFR-Targeting ADC Candidate HLX42
2023-11-21

Fosun International Receives “Excellence in Environmental Positive Impact Commendation” at Hong Kong ESG Reporting Awards
2023-11-20

A New Record, Fosun Pharma Ranks 2nd in the 2022 Top 100 Companies in China's Pharmaceutical Industry
2023-11-20

Fosun International Wins Multiple Awards Including “The Asset ESG Corporate Awards 2023 – Platinum Award”, “Best Sustainability Team” and “Best Investor Relations Team” from The Asset